[Effect of fluvastatin extended release on the protein-lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia].
The aim of the study was to estimate the effects of 4-weeks therapy of fluvastatin extended release (XL) on lipids serum, C-reactive protein (CRP), erythrocyte structure membrane (thiobarbituric acid reactive substances--TBARS concentrations, membrane cholesterol and the activity of Na+K(+)-ATPase in erythrocytes) in patients with hyperlipidemia without any clinical signs of atherosclerosis.


METHODS
The study comprised 37 persons, including 15 healthy volunteers and 22 patients with hyperlipidemia (TC > 200 mg/dl, LDL-C > 130 mg/dl, TG < 400 mg/dl) treated with fluvastatin XL 80 mg/d. Before and after 4 weeks of active treatment the following parameters were determined: lipids (by enzymatic method using BioMerieux tests), CRP (by immunoturbidimetric method), TBARS concentrations (by method of Stock and Dormandy), membrane cholesterol (method of Ilcy), Na+K(+)-ATPase activity (method of Bartosz et al.).


RESULTS
It was noticed significantly higher concentrations of CRP, TBARS, membrane cholesterol and lower activity of Na+K(+)-ATPase in erythrocytes of patients with hyperlipidemia than in the control group. Fluvastatin XL caused a significant decrease in serum TC (by 18%), LDL-C (by 24%), TG (by 16%), CRP (by 23%) and TBARS (by 31%), membrane cholesterol (by 30%) in comparison to the initial values before active therapy. The activity of Na+K(+)-ATPase didn't significantly change. The mean values of CRP, TBARS, membrane cholesterol level after active treatment are still higher than in the control group.


CONCLUSIONS
The short-term treatment of fluvastatin extended release wasn't enough efficient to compensate disorders in erythrocyte membrane structure of patients with hyperlipidemia.
Broncel
Marlena
M
Uniwersytet Medyczny w Lodzi, Klinika Chorób Wewnetrznych z Oddziałem Farmakologii Klinicznej i Terapii Monitorowanej. ttm@ttm.org.pl
Balcerak
Madgalena
M
Cieślak
Dorota
D
Duchnowicz
Piotr
P
Koter-Michalak
Maria
M
Sikora
Joanna
J
Chojnowska-Jezierska
Julita
J
D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004910:Erythrocyte Membrane / Q000187:drug effects* / Q000378:metabolism; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage*; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism*; D007211:Indoles / Q000008:administration & dosage*; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D003692:Delayed-Action Preparations; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D000077340:Fluvastatin; D002097:C-Reactive Protein